BillionToOne Welcomes Anthony Pagano as New Board Member
BillionToOne, Inc. (NASDAQ: BLLN), an innovative molecular diagnostics company, has made a significant move in its leadership by announcing the appointment of Anthony Pagano to its Board of Directors. This change will take effect starting January 1, 2026. Anthony Pagano brings a wealth of experience to the role, also serving as the Chair of the Audit Committee.
Experience and Growth at Genmab
Currently, Mr. Pagano serves as Chief Financial Officer at Genmab, a well-recognized international biotechnology firm. He has excelled in this position since March 2020 after joining the company in December 2007. His leadership has been pivotal in driving financial success and strategic advancements of Genmab, helping it grow its annual revenues from a modest $100 million to over $3 billion. Under his stewardship, Genmab has transformed into a leader in developing innovative antibody therapeutics that significantly enhance patient outcomes.
Professional Background and Credentials
Prior to his current role at Genmab, Pagano held various key positions, including Corporate Controller and Senior Director of Business Planning at NovaDel Pharma, a publicly traded specialty pharmaceutical company. He began his career at KPMG LLP, where he provided vital audit and consulting services across various industries, ranging from startups to established Fortune 500 companies.
Education and Professional Designation
Mr. Pagano is a Certified Public Accountant, having received his Bachelor of Science in Accounting from The College of New Jersey. He furthered his education with an MBA from the prestigious Stern School of Business at New York University, which bolstered his expertise in financial management and corporate strategy.
Vision for the Future
In expressing his excitement about joining BillionToOne, Pagano stated, "BillionToOne is at the forefront of precision diagnostics, and I am honored to support this important mission. I have observed how innovation in life sciences can bring about genuine change, and I am genuinely impressed by the capabilities of BillionToOne's technology and the dedication of its team. I am eager to align with the Board and management as the company embarks on its next phase of growth."
Leadership Views on the Appointment
Dr. Oguzhan Atay, co-founder and CEO of BillionToOne as well as the Chairman of the Board, remarked, "The addition of Anthony to our Board greatly enhances our governance. His extensive financial expertise and successful track record in high-growth life sciences firms will play a crucial role in our ambition to establish BillionToOne as a transformative force in molecular diagnostics."
About BillionToOne
Based in Menlo Park, California, BillionToOne is dedicated to transforming molecular diagnostics by creating highly effective and accessible tests. Their patented Quantitative Counting Templates™ (QCT™) platform stands out in the field as the only technology capable of accurately counting DNA molecules at the level of individual molecules.
Frequently Asked Questions
What is the role of Anthony Pagano at BillionToOne?
Anthony Pagano has been appointed as a Board member and will also serve as the Chair of the Audit Committee.
What experience does Anthony Pagano bring?
He has extensive experience as CFO of Genmab and has contributed to substantial revenue growth there, alongside previous roles in other significant companies.
What is the mission of BillionToOne?
BillionToOne aims to create powerful and accurate molecular diagnostics that are accessible to all, leveraging their specialized technology.
Where is BillionToOne headquartered?
The company is headquartered in Menlo Park, California.
What technology underpins BillionToOne's services?
The firm utilizes its patented Quantitative Counting Templates™ (QCT™) technology, which allows for precise DNA molecule counting.
